The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) injections as an add-on therapy for adults with chronic obstructive pulmonary disease (COPD) who continue to struggle ...

Nucala (mepolizumab) and Dupixent (dupilumab) are brand-name subcutaneous injections ... eosinophilic chronic obstructive pulmonary disease (COPD) in adults • eosinophilic asthma in adults ...

The Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of chronic obstructive pulmonary disease (COPD ...

In the 106-patient study, 41% of Dupixent-treated patients achieved a 90% or greater reduction in disease severity, compared to 10% of the control group, while "clinically meaningful" itch ...

Dupixent for the treatment of COPD has been approved in more than 45 countries worldwide, including the 27 member countries of the European Union (EU). COPD is a chronic respiratory disease that ...

Sanofi and Regeneron's Dupixent has become the first biologic ... new treatment option for the rare and highly debilitating skin disease. The two companies are still waiting for the results ...

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch Dupixent also ...

Dupixent approved as the first-ever biologic medicine in Japan for patients with COPDFollowing recent approvals in the EU, China, and the US, ...

The sBLA is based on data from a pivotal study that demonstrated that Dupixent led to significant improvements in sustained disease remission compared to placebo in adult patients with moderate-to ...

Dupixent for the treatment of COPD has been approved in more than 45 countries worldwide, including the 27 member countries of the EU. COPD is a chronic respiratory disease that damages the lungs ...